Mayo Foundation for Medical Education and Research

University of California

Euroimmun Medizinische Labordiagnostika Ag

Cz Biohub Sf, Llc.

Thomas J Kryzer

Vanda A Lennon

Andrew McKeon

Sean J Pittock

Shannon Hinson

Boyan Fang

Lars Komorowski

Yvonne Denno

Ramona Miske

Madeleine Scharf

Christiane Radzimski

Joseph L DeRisi

Stefanie Hahn

Josephe A Honorat

Mandy Unger

Divyanshu Dubey

Brian O'Donovan

Michael R Wilson

Caleigh Mandel-Brehm

Guy E Griesmann

Edward H Lambert

James P Fryer

Avi Gadoth

This disclosure describes methods and compositions for detecting the presence of a Kelch-like protein 11 autoantibody in a biological sample. Also provided are methods of treating subjects with testicular cancer or a premalignant condition and paraneoplastic encephalomyelitis.

Autoantibodies as biomarker of paraneoplastic encephalitis associated with testicular cancer

This document provides methods and materials involved in identifying and treating autoimmune GFAP (glial fibrillary acidic protein) astrocytopathy, a novel meningoencephalomyelitis, in humans as well as methods and materials for identifying and offering early treatment for patients having autoimmune GFAP astrocytopathy whose autoantibody profile predicts a high likelihood of having underlying cancer (e.g., adenocarcinoma or teratoma).

Methods and materials for identifying and treating autoimmune GFAP astrocytopathy

A method for diagnosing a disease can include detecting, in a sample from a patient, an autoantibody binding to Septin-7. A polypeptide comprising Septin-7 or a variant thereof can be used for the diagnosis of a disease. Preferably, the polypeptide is used to detect an autoantibody binding to Septin-7 in a sample. A kit is useful for the diagnosis of a disease. The kit may include a polypeptide that includes Septin-7 or a variant thereof or a medical device that includes a polypeptide that includes Septin-7 or a variant thereof and an autoantibody to Septin-7.

Autoantibodies to Septin-7 and diagnosis of neurological disease

This document provides methods and materials for detecting PCA-2-specific autoantibodies, which can be associated with paraneoplastic neurological disorders and cancers associated with PCA-2-specific autoantibodies.

Materials and methods for evaluating and treating cancer

The present invention provides for methods and materials for diagnosing and treating neuromyelitis optica (NMO).

Methods of treating neuromyelitis optica (NMO)

Method of detecting a neuromyelitis optica specific-autoantibody by an antigenic aquaporin-4 polypeptide

Marker for neuromyelitis optica

An immunoassay for small cell lung carcinoma is provided which uses small cell lung carcinoma voltage-gated calcium channel antigen (SCC-VGCC Ag) comprising a detectable label and antibodies against SCC-VGCC Ag to detect endogenous SCC-VGCC Ag.

Immunoassay for small cell lung carcinoma

Growing community of inventors

Mantorville, MN, United States of America

Thomas J Kryzer